OncoNov delivers daily updates on cancer research, diagnostics, clinical trials, and treatments, providing clinicians and patients with the latest breakthroughs.
The phase 2 AZUR-1 trial has met its main goal, showing that dostarlimab (Jemperli) alone can produce a lasting complete response in patients with stage II/III dMMR/MSI-H locally advanced rectal...
Researchers have identified a new metabolic pathway that helps cancer cells grow and spread. The study, published in Nature Communications, reveals how changes in cell metabolism can directly activate...
The FDA has approved Ennumo (pegfilgrastim-pccg), a biosimilar to Neulasta (pegfilgrastim), for adults and children. Developed by Accord BioPharma, it is the eighth pegfilgrastim biosimilar approved...
The FDA has expanded the approval of pembrolizumab (Keytruda) or the subcutaneous formulation Keytruda Qlex, in combination with enfortumab vedotin (Padcev), for adults with muscle-invasive bladder...
The FDA has approved a subcutaneous (under-the-skin) formulation of isatuximab-irfc (Sarclisa Escena) for all indications previously covered by the intravenous (IV) version in multiple myeloma. The...
Interim results from the phase 2 THIO-101 trial show that the investigational drug ateganosine (THIO), followed by the PD-1 inhibitor cemiplimab (Libtayo), achieved a 90.5% disease control rate in...
New data show that zoldonrasib (RMC-9805), an oral RAS G12D-targeted therapy, produced promising results in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) carrying a RAS G12D...
New data suggest that the survival benefit of DCVax-L for patients with glioblastoma (GBM) is greater than previously reported. The original phase 3 analysis showed that DCVax-L improved median...
Results from the phase 3 ELEVATE trial show that ensartinib (Ensacove) significantly reduced the risk of cancer recurrence in patients with completely resected stage IB to IIIB ALK-positive non-small...
